سياسة تحديد أسعار الأدوية الجزائرية الصنع في إطار المقاربات القانونية المستحدثة

الملخص EN

In this article, we study the pricing policy of medicines used in Algeria for both imported (FOB price) and locally manufactured (PCSU) products, including the setting of both Algerian public price (PPA) and the reference price (TR) for retail products, highlighting the role of this price regulation in encouraging the development of a local pharmaceutical industry and reducing the import bill that decreased from more than 2 billion dollars in 2012 to about 1 billion dollars in 2022, by promoting and expanding generics consumption given their low prices compared to those of original drugs (princeps) that also recently decreased by about 9% with the arrival of these competitive generics.

the aim of this study is to identify the mechanisms of the price regulation in Algeria, concluding that the process is mainly based on comparative analysis with prices of medicines from the same therapeutic area marketed locally and/or internationally in addition to considering the pharmacoeconomic studies and taking into account both integration rate and the variation of exchange rates.